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INTRODUCTION
Carcinoembryonic antigen (CEA) and carbohy-
drate antigen (CA)19-9 are widely known as the
most common tumor markers of colon cancer, and
levels are used not only for the preoperative assess-
ment of extent and outcome of cancer, but also for
postoperative monitoring of recurrence. Combined
data on preoperative increases in CEA and CA19-9
in sera can help predict the prognosis of patients
with colorectal carcinoma (1).
We encountered a patient with abnormally high
preoperative serum levels of CEA (311.1 ng/ml)
and CA19-9 (5731.2 U/ml), with no sign of metas-
tases on computed tomography (CT) or 18F-fluoro-
deoxyglucose (FDG)-positron emission tomography
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(PET)/CT. After performing sigmoidectomy with
lymph node dissection, CEA and CA19-9 levels nor-
malized even without further administration of anti-
cancer treatments. This represents the first report
of extremely high serum levels of CEA and CA19-
9 in a patient with advanced colon cancer but no
metastases.
CASE REPORT
In August 2010, a 69-year-old Japanese healthy
woman noticed occult blood in her feces. No rele-
vant medical history was elicited. She did not smoke
or drink alcohol. Colonoscopy was performed and
sigmoid colon cancer was diagnosed (Fig. 1). Bio-
chemical analysis of serum showed : CEA, 311.1
ng/ml (normal, 0.0-5.0 ng/ml) ; and CA19-9, 5731.2
U/ml (normal, 0.0-37.0 U/ml). FDG-PET/CT was
performed, but did not reveal any metastases (Fig.
2a, b).
Sigmoidectomy with lymph nodes dissection was
performed. No dissemination into the intraabdomi-
nal space was identified. The resected specimen was
diagnosed as advanced colon cancer without lymph
node metastases. Pathological analysis revealed well-
differentiated tubular adenocarcinoma cells infiltrat-
ing to the subserosa (pSS, ly0, v0, pN0). No anti-
tumor agents were administered immediately post-
operatively. Postoperative serum levels of CEA and
CA19-9 are shown in Figure 3. No recurrence of
sigmoid colon cancer had been detected as of 18
months postoperatively.
Immunohistochemical studies revealed high ex-
pression of both CEA and CA19-9 in tumor cells of
the resected specimen (Fig. 4b, c).
Figure 2 : FDG-PET/CT.
a) Coronal FDG-PET/CT. Arrowhead shows the primary lesion
in the sigmoid colon.
b) Axial FDG-PET/CT. Arrowhead shows the primary lesion in
the sigmoid colon.
SUVmax=15.9
Figure 1 : Colonoscopy.
Arrowheads show advanced sigmoid colon cancer (Type 2, size ;
2.81.5 cm).
Figure 3 : Changes in CEA and CA19-9 concentrations.
a) Y-axis : CEA concentration (ng/ml).
X-axis : 1) preoperative day 1 ; 2) postoperative day 1 ; 3) post-
operative day 10 ; 4) postoperative day 21 ; 5) postoperative day
40 ; 6) postoperative day 60.
b) Y-axis : CA19-9 concentration (U/ml).
X-axis : 1) preoperative day 1 ; 2) postoperative day 1 ; 3) post-
operative day 10 ; 4) postoperative day 21 ; 5) postoperative day
40 ; 6) postoperative day 60.
The Journal of Medical Investigation Vol. 59 August 2012 281
DISCUSSION
CEA is a high molecular weight glycoprotein that
plays a pivotal role in biological phenomena such as
adhesion, immunity and apoptosis of the tumor cells
(2). CA19-9 recognizes sialyl LewisA, a glycoprotein
present with cancers such as colon cancer, pancre-
atic cancer, and biliary tract cancer. Sialyl LewisA
is involved in cancer cell adhesion to endothelium
and metastases via selectin interactions (3). Serum
levels of CEA and CA19-9 correlate with histologi-
cal progression of tumors and the degree of metasta-
sis and allow the evaluation of prognosis for patients
with colon cancer (1, 4, 5). Sun et al. reported that
patients with serum CEA levels5 ng/ml were 2.38
times more likely to die of cancer than those with
serum CEA levels 5 ng/ml, based on cancer -
specific survival (5). Conversely, Park et al. reported
high preoperative CA19-9 levels as an independent
prognostic factor for recurrence, but among patients
with recurrence, 21.4% showed a high postoperative
CA19-9 (4). In the present case, the abnormally high
levels of CEA (311.1 ng/ml) and CA19-9 (5731.2
U/ml) detected in serum preoperatively required
attempts to detect metastases, but none were appar-
ent on FDG-PET/CT (Fig. 2a, b). Sigmoidectomy
was therefore performed with lymph node dissec-
tion. Operative specimens revealed no metastases
to lymph nodes. This represents the first report to
identify extremely high serum levels of both CEA
and CA19-9 in a patient with colon cancer without
metastases. Postoperatively, we did not immediately
administer anti-tumor agents to allow observation
of the natural course of CEA and CA19-9 levels.
The half-lives of tumor markers are not well
known. Yoshimasu et al. reported mean half-lives of
1.5 days for CEA and 0.5 days for CA19-9 (6). In this
case, the half-lives of CEA and CA19-9 were 10
days (Fig. 3a, b). Although we could not determine
the exact half-lives, these results indicated curative
operation. No recurrence of sigmoid colon cancer
had been observed by 18 months postoperatively.
Reasons for elevated serum levels of CEA and
CA19-9 remain unclear in general. In the present
case, both CEA and CA19-9 were highly expressed
in the resected tumor cells (Fig. 4). Excessive ex-
pression of both CEA and CA19-9 by tumor cells
would thus have drained into surrounding vessels
and resulted in high serum levels.
In conclusion, we encountered a rare case of sig-
moid colon cancer with abnormally high levels of
the tumor markers CEA and CA19-9, but with no
metastases. FDG-PET/CT offers a useful tool for
preoperative evaluation of colon cancer metastases
in such cases.
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